Licensees Sought For Osteotech Grafton DBM; Firm Cuts Workforce By 5%
This article was originally published in The Gray Sheet
Executive Summary
Osteotech aims to improve domestic sales of its Grafton demineralized bone matrix business by initiating licensing deals with large orthopedic players
You may also be interested in...
Smith & Nephew Inks Osteotech For DBM, Launches Varicose Vein Remover
Smith & Nephew will enter the demineralized bone matrix (DBM) market in the third quarter through a distribution deal with Osteotech
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”